Search

Your search keyword '"Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie" Remove constraint Author: "Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie"
41 results on '"Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie"'

Search Results

1. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

2. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

3. Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study

4. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure

5. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study

6. Stump closure reinforcement with absorbable fibrin collagen sealant sponge (TachoSil®) does not prevent pancreatic fistula after distal pancreatectomy: the FIABLE* multicenter controlled randomized study

7. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

8. Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study

9. Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care

10. Tight junction proteins in gastrointestinal and liver disease

11. Direct-acting antiviral agent–based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study

12. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment a prospective cohort study

13. Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis

14. Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity

15. Safety of sofosbuvir-based regimens after liver transplantation longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

16. Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes

17. A Global Interactome Map of the Dengue Virus NS1 Identifies Virus Restriction and Dependency Host Factors

18. Carcinome hépatocellulaire après éradication du virus de l’hépatite C par les antiviraux à action directe

19. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses

20. Integrative analysis of CD8 T-cell responses in the context of adaptive immunity to acute Hepatitis C virus infection

21. Clinical development of hepatitis C virus host-targeting agents

22. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

23. Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)

24. Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease

25. Hepatitis C virus entry and cell-cell transmission : implication for viral life cycle and antiviral treatment

26. Hepatitis C virus entry and cell-cell transmission : implication for viral life cycle and antiviral treatment

27. Evaluation préclinique de thérapies innovantes pour le carcinome hépatocellulaire et l'infection chronique par le virus de l'hépatite C

28. Etude du rôle des protéines cellulaires RACK1 et TIP47 dans l'infection par le virus de l'hépatite C

29. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes using monoclonal antibodies

30. Etude des facteurs cellulaires responsables de l'initiation et de la dissémination du virus de l'hépatite C

31. Etude des facteurs cellulaires responsables de l'initiation et de la dissémination du virus de l'hépatite C

32. A bile acid transporter as a candidate receptor for hepatitis B and D virus entry

33. Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization

34. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission

35. Study of viral and cellular factors involved in hepatitis C virus escape during liver transplantation

36. Potent calcium phosphate nanoparticle surface coating for in vitro and in vivo siRNA delivery: a step toward multifunctional nanovectors

37. An Aboriginal Australian Genome Reveals Separate Human Dispersals into Asia

38. Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study

39. Hepatitis B Virus Core Variants, Liver Fibrosis, and Hepatocellular Carcinoma

40. Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis

41. Plasmodium P36 determines host cell receptor usage during sporozoite invasion

Catalog

Books, media, physical & digital resources